Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00262093
Status:
UNKNOWN
Last Update Posted:
2007-03-20
First Post:
2005-12-04
Brief Title:
Angiogenesis Markers in Primiparas Versus Multiparas Relevance to Preeclampsia Incidence
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
Angiogenesis Markers in Primiparas Versus Multiparas Relevance to Preeclampsia Incidence
Status:
UNKNOWN
Status Verified Date:
2005-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients
Detailed Description:
Primiparity is one of the main risk factors for having preeclampsia during pregnancy Recently sFlt-1 soluble FMS-like tyrosine kinase-1 has been shown to be a major molecule involved in the pathogenesis of preeclampsia Higher sFlt-1 mRNA higher serum levels of sFlt-1 as well as lower PlGF placental growth factor have been found in preeclamptic patients
We intend to check the angiogenesis profile of primiparas as compared to multiparas
We intend to check the angiogenesis profile of primiparas as compared to multiparas
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None